WGc-043 is under clinical development by Chengdu WestGene Biopharma and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData, Phase I drugs for Nasopharyngeal Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how WGc-043’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

WGc-043 overview

WGc-043 is under the development for the treatment of Epstein-Barr virus (HHV-4) associated nasopharyngeal carcinoma and natural killer T-cell lymphoma. It comprises of lipid nanoparticle (LNP) encapsulating mRNA vaccine and is being developed based on artificial intelligence (AI) platform.

Chengdu WestGene Biopharma overview

Chengdu WestGene Biopharma (WestGene) is a biotechnology researching company that develops drugs for EBV-related tumors and liver cancer, new crown vaccines, and novel adjuvants. The company is headquartered in Chengdu, Sichuan, China.

For a complete picture of WGc-043’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.